“…There is growing interest in the scintigraphic evaluation of suspicious breast masses. Radiopharmaceuticals including fluorine-18 fluorodeoxyglucose (FDG), thallium-201, technetium-99m hexakis 2-methoxyisobutylisonitrile (MIBI), 99m Tc-tetrofosmin and 99m Tc complexes of diphosphonates such as methylene diphosphonate (MDP) and hydroxymethylene diphosphonate (HMDP) have been investigated as complements to diagnostic imaging procedures in patients with suspected breast cancer [4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37]. FDG positron emission tomography (PET) has been suggested as a reliable technique for breast cancer detection, but its use is restricted by the high cost and by manpower considerations.…”